Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.2917
+0.0332 (12.84%)
At close: Sep 12, 2025, 4:00 PM EDT
0.2793
-0.0124 (-4.25%)
After-hours: Sep 12, 2025, 7:59 PM EDT

Company Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.

The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.

Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.

The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation.

The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas.

In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive.

Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex, Inc.
Genprex logo
CountryUnited States
Founded2009
IPO DateMar 29, 2018
IndustryBiotechnology
SectorHealthcare
Employees15
CEORyan Confer

Contact Details

Address:
3300 Bee Cave Road, Suite 650-227
Austin, Texas 78746
United States
Phone877 774 4679
Websitegenprex.com

Stock Details

Ticker SymbolGNPX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001595248
CUSIP Number372446104
ISIN NumberUS3724462037
Employer ID90-0772347
SIC Code2834

Key Executives

NamePosition
Ryan M. Confer M.S.President, Chief Executive Officer, Chief Financial Officer and Director
Dr. Mark S. Berger M.D.Chief Medical Officer
David M. SchlossSenior Vice President of Human Resources
Thomas C. Gallagher Esq.Senior Vice President of Intellectual Property and Licensing
Dr. Suzanne Thornton-Jones Ph.D.Senior Vice President of Regulatory Affairs and Quality
Celina LaneyChief of Staff
Dr. Jack A. Roth F.A.C.S., M.D.Chairman of Scientific and Medical Advisory Board

Latest SEC Filings

DateTypeTitle
Sep 12, 2025S-1General form for registration of securities under the Securities Act of 1933
Sep 5, 2025DRS[Cover] Draft Registration Statement
Aug 20, 20258-KCurrent Report
Aug 18, 20258-KCurrent Report
Aug 15, 20258-KCurrent Report
Aug 14, 202510-QQuarterly Report
Aug 5, 2025RWFiling
Aug 4, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 4, 20258-KCurrent Report
Jul 16, 2025ARSFiling